Connect with us


Fairtility unveils CHLOE OQ™ expanding its offering into fertility preservation

CHLOE OQ™ secures CE, empowering embryologists and patients with oocyte quality insights for egg freezing, egg donation and IVF applications



Fairtility's CHLOE OQ™ aims to empower embryologists and patients with oocyte quality insights for egg freezing, egg donation and IVF applications
Fairtility, the transparent AI innovator powering reproductive care for improved outcomes, has announced the launch of CHLOE OQ™, bringing Oocyte Quality Insights to CHLOE’s core technology suite of capabilities and expanding the applicability of its AI-driven decision support tool to fertility preservation.

The solution will be unveiled at the 39th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) being held in Copenhagen, Denmark from June 25 to 28, 2023.

With CE declared for CHLOE OQ™, the new Oocyte Quality Insights capability offers IVF professionals comprehensive information to support decision making as patients undergo fertility preservation or assisted reproductive journeys.

The tool delivers predictions of an oocyte’s potential to reach the blastocyst stage post-fertilisation.

“Assessing fertility potential involves understanding three factors: sperm, oocytes and embryos. We can evaluate the viability of embryos and understand sperm quality. However, assessing oocyte quality has remained a statistical gamble,” said Dr Cristina Hickman, chief clinical officer of Fairtility.

“When looking at a seemingly ‘good’ oocyte, we can’t really identify which one will become a blast after fertilisation. CHLOE OQ helps us fill the critical gap, providing evidence-based viability predictions for the evaluation of oocytes.

“This will help clinicians to provide transparency to patients while discussing a failed IVF cycle in fertility preservation, or when assessing and allocating donor eggs.”

Oocyte quality assessment commonly relies on statistical methods based on a woman’s age. Embryologists analyse oocyte quality based on oocyte maturity and characteristics including size, texture, shape, discoloration and fragmentation.

However, these factors have proven to be subjective and lack correlation with the actual quality of the egg.

CHLOE OQ brings the power of AI to oocyte assessment, replacing generalised decision-making with personalised, data-driven AI analysis that reveals the potential of each oocyte backed by biological data.

CHLOE OQ offers personalised data to support decision making for three key applications:

  • Egg freezing: In the process of fertility preservation, IVF professionals may recommend an additional oocyte retrieval based on the raw number of oocytes retrieved. While CHLOE OQ cannot change the biology of the egg, it can assist in providing a personalised assessment and managing expectations for family planning early on. CHLOE OQ helps IVF professionals and patients make informed decisions on whether to undergo an additional oocyte retrieval cycle. The tool is designed to optimise the chances of successful IVF in the future and gives women greater control of their reproductive opportunities later in life.
  • Egg donation: CHLOE OQ helps fertility clinics and egg banks to further assess the quality of donor eggs, ensuring equitable distribution to recipients. By leveraging data-driven insights, donor-egg providers may match recipients with the most suitable donor eggs, increasing the chances of successful IVF outcomes, maximising limited donor egg resources and enhancing the donor-recipient experience.
  • IVF treatment: During IVF, older patients are often guided to utilise donor eggs based on age rather than the true quality of their eggs. At 40-years of age, approximately 10 per cent of patients utilise their own eggs, and by 44-years old, this number drops to one per cent. CHLOE OQ is expected to help IVF professionals consider if a patient’s own eggs have sufficient quality for a successful IVF treatment, or if an egg donor may be a more suitable option. This reduces costs for patients undergoing IVF and maximises egg donor resources. A better understanding of oocyte quality also provides IVF professionals insight on an oocyte’s role in a failed IVF cycle, enabling better treatment decisions for future IVF cycles.

“Adding oocyte analysis broadens CHLOE’s core technology capabilities, extending beyond embryo assessment for IVF. CHLOE OQ now provides decision support for fertility preservation, egg donation, and female-factor infertility in IVF treatment. This expansion allows us to assist a larger population seeking to secure their reproductive futures,” stated Eran Eshed, CEO and co-Founder of Fairtility.

“While we can’t halt the passage of time and the consequent decline in oocyte quality, we can effectively freeze it. With CHLOE OQ, patients, through their fertility care team, can gain transparency into their oocytes’ viability, enabling proactive management of their reproductive health and facilitating well-informed decisions based on biological data.”

CHLOE’s core technology is the first and only decision support tool that combines AI-driven analysis of embryos and oocytes with explainable biological insights in terms that IVF professionals understand and can trust.

This supports data-driven and consistent decision-making in the IVF lab, with a goal of optimising outcomes, making fertility care more efficient and creating new family-building possibilities.


Apricity Fertility launches new Freeze and Share programme

The Freeze and Share programme offers a solution for women who wish to preserve their fertility



In response to the growing demand for affordable fertility options and the pressing need for egg donors, the UK virtual fertility clinic Apricity has launched an innovative Freeze and Share programme.

The initiative is designed to make egg freezing more accessible and cost-effective while simultaneously addressing the shortage of donor eggs in the UK.

In recent years, there has been a significant increase in the number of women choosing to freeze their eggs. According to the Human Fertilisation and Embryology Authority (HFEA), the number of egg freezing cycles in the UK has surged by 81 per cent to 2022. Despite this growing trend, the high costs associated with the procedure—typically upwards of £5000—have made it unaffordable for many.

The Freeze and Share programme offers a solution for women who wish to preserve their fertility; by opting to share their eggs, they can substantially reduce the cost of egg freezing.

This act not only makes the procedure more affordable but also provides much longer for donor eggs for those that need them.

Addressing the egg donor shortage

The UK faces a shortage of egg donors, with many patients experiencing long waiting times for a donor. Current statistics reveal that one in six IVF cycles are donation cycles in the UK, yet demand far outstrips supply.

Prospective parents can wait up to two years to find a suitable donor, and for many they decide to travel abroad to places like Spain and Cyprus. This brings different considerations for patients as egg donation in other countries is regulated differently to the UK, with most egg donation being completely anonymous. 

Apricity’s new programme directly addresses this gap by encouraging egg sharing. Participants in the Freeze and Share programme can donate a portion of their eggs to be used by individuals or couples in need, thereby reducing waiting times and helping more people achieve their dreams of parenthood.

“We are incredibly proud to launch our Freeze and Share Programme, which represents a significant advancement in our fertility services,” said Mel Chacksfield, CEO of Apricity Fertility.

“This new service will not only make egg freezing more accessible and affordable to the many women who may not usually have the chance to preserve their fertility, but will also mean we can better support our families and parents that rely on donor eggs to start their families.

“Our commitment to providing personalised care through innovation in the sector continues to drive us forward, ensuring we meet the evolving needs of all our patients”

To be eligible for egg sharing, women will need to meet specific criteria such as BMI, age and ovarian reserve. They will have unlimited counselling throughout the process to ensure they are fully informed and supported from the start.

Women who choose to participate in the Freeze and Share programme will then undergo the standard egg freezing process. A portion of the retrieved eggs will be frozen for their personal use, while the remaining eggs will be donated to Apricity’s frozen egg donor bank.

This mutually beneficial arrangement ensures that participants receive significant financial relief while offering a lifeline to those in need of donor eggs.

For more information on Freeze & Share visit Apricity’s website 

Continue Reading


Endometriosis needs to be taken as seriously as diabetes, says report



A new report, which called for “urgent” changes in endometriosis care, has said the condition should be taken as seriously as diabetes.

The National Confidential Enquiry into Patient Outcome and Death (NCEPOD) report examined the long-standing issues faced by women with endometriosis in the UK.

The study stated that endometriosis should be treated as a chronic condition and taken as seriously as illnesses such as diabetes and bowel disease.

Currently, endometriosis symptoms are treated as multiple isolated episodes, with symptoms often going unrecognised by healthcare practitioners as potentially being endometriosis.

The report recommended that training for healthcare professionals should be improved to recognise the symptoms of endometriosis and that patients should be asked about how the condition affects them beyond just the physical symptoms.

Professor Andrew Horne, director of the University of Edinburgh’s Centre for Reproductive Health, said: “Endometriosis is frequently treated as a series of acute episodes rather than as a continuous, chronic condition. This fragmented care model overlooks the necessity for ongoing, comprehensive management, which is crucial.

“The NCEPOD report recognises the gaps in our current approach and provides important actionable guidance to drive improvements in endometriosis care.”

Emma Cox, CEO of Endometriosis UK, said: “NCEPOD’s report clearly evidences the issues faced today by those with endometriosis, and the recommendations show how improvements can – and must – be made. Implementing these will not only reduce suffering for those with endometriosis, it will also save the NHS time and resources.

“The report comes at a perfect time; we have a new government who have committed to no longer neglect women’s health, and to prioritise women’s health as the NHS is reformed.”

Dr Katy Vincent, associate professor in the Nuffield Department of Women’s and Reproductive Health, University of Oxford, added: “Endometriosis affects all areas of life and the information collected by this enquiry starkly illustrates the challenges that those with the condition experience.

“I am particularly pleased to see that the report highlights the need for holistic, multi-disciplinary care and for a pathway that takes into account the chronic nature of the disease, as these are areas that I have long considered need improvement.”

She continued: “I hope that those who contributed their experiences to the report feel they were heard and that clinicians and policy makers can now take these findings on board to urgently improve care for this common condition.”

To receive the Femtech World newsletter, sign up here.

Continue Reading


Daye launches workplace app to plug gaps in female healthcare support

The service helps promote health equity in the workplace by providing vital resources to support women’s health conditions



The award-winning UK gynaecological health company Daye has launched its new workplace app, Daye for Work.

The app can be offered to employees across the UK as a workplace benefit, providing them with much-needed access to services that are often lacking from the NHS and even private healthcare companies.

Women face a widening gap in healthcare provision, with three-quarters saying they cannot access the services they need and 84 per cent reporting not being listened to by a healthcare professional.

Health issues can have a big impact on women’s careers, with three in five women saying a female health condition has affected them in the workplace.

However, support for women’s health is often lacking in the workplace. According to Benden Health, four in ten women have heard derogatory comments about a female employee’s health in the workplace.

As a result, 42 per cent of females admit that they are uncomfortable discussing health issues with their manager.

In addition, more than two thirds of female employees (70 per cent) have found it difficult to deal with periods at work and 64 per cent have faced challenges when experiencing menopause.

Offering support to employees struggling with female health conditions can help attract and retain staff, with 70 per cent of workers willing to change jobs for women’s health benefits.

Daye for Work provides an accessible and personalised service for women and assigned female at birth (AFAB) individuals.

Through the app, employees of businesses who sign up for Daye for Work can access Daye’s Menstrual Health Programme, which provides access to period pain support, plugging a major gap in healthcare provision as it can take years to diagnose conditions linked to menstrual health, such as endometriosis and adenomyosis.

Currently, menstrual pain support is also not offered by major private healthcare providers. Yet period pain can be so severe that nearly a quarter of women (23 per cent) have taken time off work for menstrual symptoms in the last six months, with nine days of productivity per woman lost every year, according to the British Medical Journal.

In monetary terms, women can lose tens of thousands during their careers as they are forced to take time off work.

Daye for Work also offers a Gynae Health Screening Programme, where users can access specialists for gynaecological-related health issues, such as recurrent vaginal infections, which is another service lacking through the NHS and private healthcare companies.

While users can access help from leading specialists through instant virtual appointments, Daye also offers at-home diagnostic tampon tests that can detect vaginal infections and STIs such as chlamydia and gonorrhoea, and soon they will also be able to detect HPV, which is the biggest cause of cervical cancer.

Users receive clear, actionable results via the platform and have prescriptions delivered to their homes.

Daye also offers educational support programmes, including workshops and webinars covering hot topics in female health, and HR policy and internal comms support. Employees signed up through their company get 20 per cent off products on the Daye website.

Valentina Milanova, founder and CEO of Daye, said: “Gaps in women’s health provision are impacting workplaces all over the UK. Female and AFAB staff are regularly forced to take time off while struggling to access much-needed support, advice and diagnosis, hitting workplace productivity and all too often being detrimental to women’s careers.

“Daye for Work will play a vital role in plugging the gaps in female healthcare, offering services that take years to access on the NHS and aren’t available from private healthcare providers.

“Offering such tailored support is transformational for workplace culture, making staff feel valued and understood, while also helping to attract and retain talent.”

Continue Reading


Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.